Analysis Of Long-term Efficacy Of Different Antiviral Regimens For Hepatitis B Patients In Yanbian Area

Objective:To search for the optimal antiviral treatment method for hepatitis B by assessing the efficacy of various antiviral therapies to patients with chronic hepatitis B and patients with compensated hepatitis B cirrhosis.Methods:This study was approved by the medical ethics committee of the hospital.A total of 53 hepatitis B patients who participated in the National Major Scientific and Technological Project titled“Effect of Long-term Antiviral Therapies on Reversal and Long-term Prognosis of Hepatitis B Hepatic Fibrosis/Cirrhosis”during the 13^thFive-Year Plan were selected who met the criteria with complete data after 260 weeks of follow-up.Patients were divided into the chronic hepatitis B group（n=19）and the compensated hepatitis B cirrhosis group（n=34）according to the initial diagnosis results.Based on medication test types,patients in the chronic hepatitis B group were then divided into the entecavir treatment group and the entecavir plus interferon treatment group and those in the compensated hepatitis B cirrhosis group were divided into the entecavir treatment group and the entecavir plus thymosin treatment group.Finally,basic data（age,gender,drinking history,smoking history,family history of hepatitis B,family history of liver cancer,weight,laboratory indicators,and imaging tests）prior to the treatment and clinical data（laboratory indicators and imaging tests）after 260 weeks of antiviral treatment of each group were collected.SPSS26.0 software was used for statistical analysis.Results:1.After 260 weeks of entecavir treatment,the decrease of ALT and AST levels and the increase of ALB level in patients of the chronic hepatitis B group were higher than those of the cirrhosis group,with statistically significant differences（P<0.05）.The percentages of ALT and AST reduction in the chronic hepatitis B group were higher than those in the cirrhosis group and the differences were statistically significant（P<0.05）.2.For patients in the chronic hepatitis B group,the decreased levels of AST,APRI,and FIB-4 as well as the increased level of ALB in the entecavir treatment group were higher than those in the entecavir plus interferon treatment group after 260 weeks of treatment and the differences were statistically significant（P<0.05）.In addition,the percentages of AST and APRI reduction of the entecavir group were higher than those of the entecavir plus interferon group,with statistically significant differences（P<0.05）.3.For patients in the compensated hepatitis B cirrhosis group,no statistically significant differences were observed in the increased or decreased indicator levels among different treatment groups after 260 weeks of treatment（P>0.05）.Conclusions:1.ALT and AST recovery is better in patients with chronic hepatitis B after long-term entecavir-based antiviral treatment than patients with compensated hepatitis B cirrhosis.2.AST and ALB recovery in patients with chronic hepatitis B treated with long-term entecavir monotherapy is better than that in those treated with long-term entecavir plus interferon;and the reduction of APRI and FIB-4 of the former group is larger.3.There is no difference in the efficacy of entecavir vs.entecavir plus thymosin as long-term treatment for patients with compensated hepatitis B cirrhosis.